Stanford University: Myelodysplastic Syndromes trials
The registry lists 15 Myelodysplastic Syndromes studies with Stanford University as lead sponsor. 4 are open to participants now and 4 have results posted.
Phase 1 6Phase 2 6No phase 5(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell TransplantNot yet recruitingNCT07634536Phase 2
- TACrolimus Targeted Immunosuppression Cessation in ALlogeneic HCTRecruitingNCT07302776Phase 1
- Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCTRecruitingNCT06551584Phase 1
- Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With CancerRecruitingNCT05297734Not applicable
- Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell TransplantationCompletedNCT03734601Phase 2Results posted
- Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With CancerCompletedNCT03154190Not applicableResults posted
- Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T CellCompletedNCT01660607Phase 1/2Results posted
- Azacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDSTerminatedNCT01442714Phase 2Results posted
- Biologically Focused Therapy of Treatment-Refractory MDS PatientsCompletedNCT05245032
- Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted GraftActive, not recruitingNCT05088356Phase 1
- Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCTTerminatedNCT02728700Phase 1
- Non-Myeloablative Allogeneic Transplant for Myelodysplastic Syndromes and Myeloproliferative DisordersCompletedNCT00186576Not applicable
- Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic MalignanciesCompletedNCT00186342Not applicable
- TLI & ATG for Non-Myeloablative Allogeneic Transplantation for MDS and MPDCompletedNCT00185796Phase 2
- Bevacizumab in Treating Patients With Myelodysplastic SyndromeCompletedNCT00022048Phase 1/2